NCT04519476 2023-10-31
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
Oncotherapeutics
Phase 1 Unknown
Clinical Trials
19 trialsNCT03759093 2023-09-06
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Phase 2/3 Unknown
NCT03809780 2023-06-22
LENDER
Kosin University Gospel Hospital
Phase 2 Unknown
NCT03641456 2023-06-18
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
Sun Yat-sen University
Phase 2 Unknown
NCT01685814 2023-04-27
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Wuerzburg University Hospital
Phase 3 Unknown
NCT05802992 2023-04-07
The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients
Affiliated Hospital of Nantong University
Phase 3 Unknown
NCT03252600 2023-01-25
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
Barbara Ann Karmanos Cancer Institute
Phase 2 Unknown
NCT05495620 2022-08-10
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
Dong-A University Hospital
Unknown
NCT05147493 2022-03-29
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
Phase 2 Unknown
NCT02575144 2022-02-01
GEM-CLARIDEX
PETHEMA Foundation
Phase 3 Unknown
NCT04818372 2021-11-12
Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
Keymed Biosciences Co.Ltd
Phase 1 Unknown
NCT04287660 2021-10-25
Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT03720041 2021-06-15
FiTNEss
University of Leeds
Phase 3 Unknown
NCT03669445 2020-07-30
IFM2018-01
University Hospital, Toulouse
Phase 2 Unknown
NCT03015922 2020-01-22
MUKeleven
University of Leeds
Phase 1 Unknown
NCT03605056 2018-07-30
Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT01554852 2018-06-11
Myeloma XI
University of Leeds
Phase 3 Unknown
NCT01010243 2012-05-30
MM03
University of Regensburg
Phase 1/2 Unknown
NCT01002703 2011-08-12
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
University of Leipzig
Phase 1/2 Unknown